Skip to main content
メニュー
Revvity logo
Contact us

Loading...

JP
Search all

Loading...

Revvity Sites Globally

Select your location.

*e-commerce not available for this region.

australia.webp Australia
austria.webp Austria
belgium.webp Belgium
brazil.webp Brazil *
canada.webp Canada
china.webp China *
denmark.webp Denmark
finland.webp Finland
france.webp France
germany.webp Germany
hong-kong.webp Hong Kong (China) *
india.webp India *
ireland.webp Ireland
italy.webp Italy
japan.webp Japan *
luxembourg.webp Luxembourg
mexico.webp Mexico *
netherlands.webp Netherlands
norway.webp Norway
philippines.webp Philippines *
republic of korea.webp Republic of Korea *
singapore.webp Singapore *
spain.webp Spain
sweden.webp Sweden
switzerland.webp Switzerland
thailand.webp Thailand *
uk.webp United Kingdom
usa.webp United States
Breadcrumb
...
  • ホーム
  • Quantifying changes in CD28 and CTLA-4 levels in peripheral blood mononuclear cells with AlphaLISA technology
quantifying-changes-cd281920
Application Note

Quantifying changes in CD28 and CTLA-4 levels in peripheral blood mononuclear cells with AlphaLISA technology

One approach to immunotherapy is the modulation of immune checkpoints that are critical in regulating the degree and duration of immune system responses and preventing autoimmunity.

In this application note, you will learn:

  • Why AlphaLISA™ technology is a useful assay for the detection and quantification of biomarkers such as CD28 and CTLA-4
  • How to run an AlphaLISA assay to detect and quantify immuno-oncology biomarkers
  • Benefits of using Alpha technology for biomarker quantification assays
  • An example of the data and analysis you can generate for biomarker assays

For research use only. Not for use in diagnostic procedures.

Download Resource

Quantifying changes in CD28 and CTLA-4 levels in peripheral blood mononuclear cells with AlphaLISA technology

Download Application Note
Revvity Logo

Loading...

    ©2025 Revvity - All rights reserved

    Revvity is a trademark of Revvity, Inc. All other trademarks are the property of their respective owners.